AbbVie Inc (ABBV)vsInnovAge Holding Corp (INNV)
ABBV
AbbVie Inc
$205.03
-0.52%
HEALTHCARE · Cap: $365.43B
INNV
InnovAge Holding Corp
$7.96
-2.57%
HEALTHCARE · Cap: $1.08B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6763% more annual revenue ($62.82B vs $915.37M). ABBV leads profitability with a 5.8% profit margin vs 0.7%. ABBV trades at a lower P/E of 100.8x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
INNV
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$168.19
Current Price
$205.03
$36.84 premium
Margin of Safety
+45.5%
Fair Value
$15.02
Current Price
$7.96
$7.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 1.2% — below average capital efficiency
0.7% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : INNV
Revenue growth of 14.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : INNV
The primary concerns for INNV are Altman Z-Score, Market Cap, Return on Equity. A P/E of 159.2x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
INNV carries more volatility with a beta of 0.49 — expect wider price swings.
INNV is growing revenue faster at 14.7% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. INNV offers better value entry with a 45.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
InnovAge Holding Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
InnovAge Holding Corp. The company is headquartered in Denver, Colorado.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?